Kratom Experts Seek NIDA As Ally To Show Herb's Safety And Benefits
This article was originally published in The Rose Sheet
Executive Summary
American Kratom Association representatives also this week are lobbying state and local officials in Georgia to withdraw their findings linking 17 deaths directly to the use of kratom, and testifying at a Utah state legislative panel hearing on alternative pain remedies.
You may also be interested in...
Kratom Industry GMPs Target Swaying FDA By Exceeding Agency Standards
“We want to show that the kratom industry is maturing, that people want to do the right thing,” says AKA Chairman Dave Herman. The standards go “well beyond” FDA's minimum GMP requirements for dietary supplements, AKA says.
Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
American Kratom Association realizes FDA could have significant influence on DEA decision on whether to schedule kratom constituent ingredients as controlled substances. The association and experts on kratom say FDA's, which concluded that mitragynine and 7-hydroxymitragynine are opioids and use of kratom is dangerous, contains numerous inaccuracies and incorrect conclusions.
FDA's Opioid Label For Kratom Called Misbranding By Marketers
"Based on the scientific information in the literature and further supported by our computational modeling and the reports of its adverse effects in humans, we feel confident in calling compounds found in kratom, opioids," says Commissioner Scott Gottlieb.